CLSTN1: A Potential Drug Target Or Biomarker (G22883)

Target Name: CLSTN1

NCBI ID: G22883

CLSTN1

CLSTN1: A Potential Drug Target Or Biomarker

CLSTN1, also known as FLJ32258, is a protein that is expressed in various tissues throughout the body, including the brain, spleen, and heart. It is a part of the CDK4 complex, a group of proteins that are involved in cell signaling.

Recent studies have identified CLSTN1 as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because CLSTN1 has been shown to play a role in the development and progression of these conditions.

One of the reasons for the interest in CLSTN1 is its role in cell signaling. CDK4 is a key regulator of cell growth and division, and is involved in many processes that are necessary for cell survival. CLSTN1 is a part of this complex, and has been shown to play a role in the regulation of cell proliferation, differentiation, and survival.

In addition to its role in cell signaling, CLSTN1 has also been shown to be involved in the development and progression of various diseases. For example, studies have shown that high levels of CLSTN1 are associated with an increased risk of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.

Another promising aspect of CLSTN1 is its potential as a drug target. By targeting the CDK4 complex and specifically CLSTN1, researchers may be able to disrupt the regulation of cell growth and division that is associated with these diseases. This could lead to the development of new treatments for these conditions.

CLSTN1 is also a potential biomarker for monitoring the effectiveness of existing treatments. By measuring the levels of CLSTN1 in cells or tissues, researchers can assess the effectiveness of different treatments and determine whether they are having the desired impact. This could be a valuable tool for the development of new treatments for various diseases.

In conclusion, CLSTN1 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Its role in cell signaling and its association with the development and progression of various conditions make it an attractive target for researchers to investigate further. Further studies are needed to fully understand the potential of CLSTN1 as a drug and biomarker.

Protein Name: Calsyntenin 1

Functions: Postsynaptic adhesion molecule that binds to presynaptic neurexins to mediate both excitatory and inhibitory synapse formation (By similarity). Promotes synapse development by acting as a cell adhesion molecule at the postsynaptic membrane, which associates with neurexin-alpha at the presynaptic membrane (By similarity). Also functions as a cargo in axonal anterograde transport by acting as a molecular adapter that promotes KLC1 association with vesicles (PubMed:21385839). Complex formation with APBA2 and APP, stabilizes APP metabolism and enhances APBA2-mediated suppression of beta-APP40 secretion, due to the retardation of intracellular APP maturation (PubMed:12972431)

The "CLSTN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLSTN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets